ClariVest Asset Management LLC cut its stake in shares of Hill-Rom Holdings Inc (NYSE:HRC) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,578 shares of the medical technology company’s stock after selling 30 shares during the period. ClariVest Asset Management LLC’s holdings in Hill-Rom Holdings were worth $3,549,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Independent Portfolio Consultants Inc. increased its stake in Hill-Rom Holdings by 171.5% in the second quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock valued at $107,000 after buying an additional 849 shares in the last quarter. Meadow Creek Investment Management LLC increased its stake in Hill-Rom Holdings by 3.9% in the first quarter. Meadow Creek Investment Management LLC now owns 1,696 shares of the medical technology company’s stock valued at $120,000 after buying an additional 64 shares in the last quarter. Neuburgh Advisers LLC increased its stake in Hill-Rom Holdings by 3.9% in the first quarter. Neuburgh Advisers LLC now owns 2,332 shares of the medical technology company’s stock valued at $165,000 after buying an additional 88 shares in the last quarter. Tyers Asset Management LLC increased its stake in Hill-Rom Holdings by 3.9% in the first quarter. Tyers Asset Management LLC now owns 2,968 shares of the medical technology company’s stock valued at $210,000 after buying an additional 112 shares in the last quarter. Finally, Bancorpsouth Inc. purchased a new stake in Hill-Rom Holdings during the first quarter valued at about $210,000. 84.27% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Hill-Rom Holdings Inc (NYSE HRC) opened at 74.44 on Wednesday. The firm has a market cap of $4.90 billion, a P/E ratio of 43.38 and a beta of 1.22. The firm has a 50 day moving average price of $79.14 and a 200 day moving average price of $73.16. Hill-Rom Holdings Inc has a 1-year low of $50.50 and a 1-year high of $84.65.

Hill-Rom Holdings (NYSE:HRC) last released its quarterly earnings data on Friday, July 28th. The medical technology company reported $0.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.90 by $0.01. The company had revenue of $689.10 million for the quarter, compared to analysts’ expectations of $695.50 million. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.81 EPS. Analysts anticipate that Hill-Rom Holdings Inc will post $3.82 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 15th will be issued a $0.18 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.97%. Hill-Rom Holdings’s dividend payout ratio is presently 41.62%.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/hill-rom-holdings-inc-hrc-shares-sold-by-clarivest-asset-management-llc/1494337.html.

Several analysts have issued reports on HRC shares. Zacks Investment Research raised Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $88.00 price target on the stock in a research note on Monday, June 12th. ValuEngine raised Hill-Rom Holdings from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. Stifel Nicolaus lifted their price target on Hill-Rom Holdings from $70.00 to $84.00 and gave the company a “buy” rating in a research note on Monday, May 1st. Barclays PLC lifted their price target on Hill-Rom Holdings from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, May 1st. Finally, Needham & Company LLC started coverage on Hill-Rom Holdings in a research note on Thursday, June 29th. They issued a “buy” rating and a $95.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $88.17.

In related news, SVP Andreas G. Frank sold 10,660 shares of the company’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $78.62, for a total value of $838,089.20. Following the sale, the senior vice president now owns 28,988 shares in the company, valued at approximately $2,279,036.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.20% of the company’s stock.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings Inc (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.